SEC Tracker
Get the app
CTMX · XBRL financial data

CytomX Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CTMX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue26,38426,607*41,46325,11533,43238,093*50,91718,6585,963663*10,2581,418
Revenue from contracts with customers26,38426,607*41,46325,11533,43238,093*50,91718,6585,963663*10,2581,418
Research and development16,44819,386*22,05225,17221,36814,790*18,86813,32215,30421,235*19,23817,598
General and administrative6,8137,827*7,7548,3957,9535,624*9,4286,6226,4277,360*10,6927,601
Total operating expenses23,26127,213*29,80633,56729,32120,414*28,29619,94421,73128,595*29,93025,199
Operating income (loss)3,123(606)*11,657(8,452)4,11117,679*22,621(1,286)(15,768)(27,932)*(19,672)(23,781)
Interest income2,6992,503*2,1941,9711,6931,278*9551,1781,5921,481*1,4903,157
Other income (expense)(7)9*(11)(2)(7)(19)*11175(5)*(7)18
Income tax expense (benefit)2,8231,069*49516162*62635854*5960
Net income (loss)2,992837*13,791(6,534)5,73618,876*23,525(154)(14,229)(26,510)*(18,248)(20,666)
Weighted average shares, basic thousands of shares80,73281,472*82,02984,88185,09385,732*87,122129,076165,004169,341*177,273218,939
Weighted average shares, diluted thousands of shares80,99281,213*82,63084,88185,20586,244*87,151129,076165,004169,313*177,273218,939
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (CTMX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents26,02417,17136,18543,24740,57638,05247,60449,04134,18512,66728,82817,224
Marketable securities168,086157,338114,09993,93577,01262,57132,282109,046109,441124,385317,879313,056
Accounts receivable2,4193,43213,1772,7753,3523,1031,9561,8691,6292,01364637,494
Prepaid and other current assets4,6754,9953,7863,1233,2403,5794,7864,6653,9624,8565,7434,464
Total current assets201,204182,936167,247143,080124,180107,30586,628164,621149,217143,921353,096373,155
Property and equipment, net4,0603,9583,5673,3162,9422,4672,2291,9461,7211,3041,0901,079
Right-of-use asset13,18412,22011,23410,2259,1938,1367,0555,9474,8143,3962,2645,037
Goodwill949949949949949949949949949949949949
Total assets221,167201,792184,687159,219138,981120,53398,497175,057158,254151,566359,358381,226
Accounts payable1,7051,4581,9646111,4221,0882762276461,3011,3681,939
Accrued liabilities20,68917,59914,22013,62016,74212,33811,40611,50312,40814,19711,92312,353
Total current liabilities146,790155,913144,536142,858119,22885,77250,20139,22341,02946,61534,02339,861
Lease liability, non-current10,5979,3858,1486,8855,5964,2402,8561,44200—4,208
Total liabilities272,405249,239216,367190,446162,433120,98973,44855,14750,86552,55839,41479,158
Accumulated deficit(724,285)(723,448)(709,657)(716,191)(710,455)(691,579)(668,054)(668,208)(682,437)(711,949)(730,197)(750,863)
Total stockholders' equity(51,238)(47,447)(31,680)(31,227)(23,452)(456)25,049119,910107,38999,008319,944302,068
Total liabilities and equity221,167201,792184,687159,219138,981120,53398,497175,057158,254151,566359,358381,226
Common shares outstanding (cover page) thousands of shares66,98967,722—78,11878,25980,10080,621164,913169,435170,187217,703217,899
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (CTMX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)2,992837*13,791(6,534)5,73618,876*23,525(154)(14,229)(26,510)*(18,248)(20,666)
Stock-based compensation1,226*2,552*1,9071,882*1,995*1,884*2,0081,431*1,384*1,479*4,7062,577*
Net cash from operating activities(18,243)*(21,963)*(26,045)(19,549)*(20,729)*(19,908)*(21,043)(15,753)*(15,548)*(23,243)*(25,549)(18,068)*
Purchases of property and equipment9*266*11596*19*80*11927*(127)*201*00*
Net cash from investing activities(42,938)*12,866*44,88521,512*18,168*15,135*30,596(76,360)*439*(14,419)*(192,777)5,953*
Proceeds from issuing common stock0*———0*2,066*093,373*0*16,262*228,35156*
Net cash from financing activities29,669*244*1745,099*0*2,249*093,550*253*16,643*234,487511*
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
CytomX Therapeutics17,2241,418(18,068)*217.9M18.3 quarters 10-QJun 30, 2026
Oruka Therapeutics268,470not reported(33,145)*66.2M26.4 quarters 10-QJun 30, 2026
Cronos Group467,01953,00724,010*368.4M— 10-QJun 30, 2026
REGENXBIO36,487108,019(62,238)*66.0M1.7 quarters 10-QJun 30, 2026
Capricor Therapeutics20,935not reported(31,485)*58.1M7.6 quarters 10-QJun 30, 2026
Cryoport269,26748,9711,131*50.6M— 10-QJun 30, 2026
Emergent BioSolutions175,700110,000100,100*51.4M— 10-QSep 30, 2026
Northwest Biotherapeutics595807(7,169)*1.7B0.1 quarters 10-QJun 30, 2026
Amarin156,51239,5509,223*not reported— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.